This PubMed entry documents a randomized clinical trial published in JAMA on August 11, 2026, titled "Adjuvant Nivolumab vs Observation in Resected Non‑Small Cell Lung Cancer: A Randomized Clinical Trial." The record identifies the work as a Clinical Trial and provides bibliographic identifiers: PMID 42224490, PMCID PMC13227333, and DOI 10.1001/jama.2026.8992. The article appears in JAMA volume 336, issue 6, pages 464–472.
The PubMed page includes links to the journal full text and a free article copy on PubMed Central, indicating full study details are available in the linked manuscript. The PubMed entry itself focuses on metadata and indexing information rather than reproducing the full abstract or trial results in the excerpt shown.
The citation lists a multicenter authorship led by Jamie E Chaft with many coauthors. Institutional affiliations span major academic cancer centers and community oncology sites across the United States, including Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, Dana‑Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Emory University Winship Cancer Institute, MD Anderson Cancer Center, Mayo Clinic, and others. The record names multiple individual investigators and their institutional affiliations as part of the published authorship.
The PubMed record classifies the work as a randomized clinical trial. Beyond that classification, the excerpt on the PubMed details page does not provide specific trial design elements in the visible content. The following key trial descriptors are not reported in the provided PubMed excerpt and therefore cannot be stated here based on this source alone: eligibility criteria, staging or histologic subtypes included, stratification factors, randomization ratio, sample size, blinding (if any), trial registration number(s), and duration of follow‑up.
For definitive methodology, the linked JAMA article and the PubMed Central full text (PMCID PMC13227333) should be consulted; those sources are indicated in the PubMed record.
The title specifies a comparison between adjuvant nivolumab and observation after surgical resection for non‑small cell lung cancer (NSCLC). The PubMed metadata does not include dosing details, treatment schedule, duration of adjuvant therapy, eligibility for adjuvant therapy (for example, nodal stage or margin status), concomitant or prior treatments, or criteria for crossover. These operational details are not reported in the PubMed excerpt and must be obtained from the full manuscript.
The PubMed entry supplies comprehensive bibliographic and authorship information but does not present the trial abstract or numeric results in the displayed excerpt. Specifically, the following were not reported on the excerpted PubMed page and therefore are not recapitulated here: primary and secondary endpoints, hazard ratios or other measures of treatment effect, p values, confidence intervals, absolute event counts, progression‑free survival or overall survival outcomes, disease‑free survival, patient‑reported outcomes, and safety and adverse event profiles.
Because these outcomes and data are central to clinical interpretation, readers should access the full text (JAMA) or the free PubMed Central copy linked in the record to review the trial findings and statistical analyses.
The PubMed page provides direct links to the JAMA full text and to the free PMC article (PMCID PMC13227333). Use those links from the PubMed record to retrieve the complete article, which should contain the methods, full results (efficacy and safety), tables and figures, supplementary materials, and any statements about trial registration and funding.
From the PubMed metadata alone we can confirm the study evaluates adjuvant nivolumab compared with observation in patients with resected non‑small cell lung cancer and that it was conducted and reported by a multi‑institutional investigator team. However, the PubMed excerpt does not report efficacy or safety outcomes or provide sufficient methodological detail to support clinical interpretation or practice change. Clinicians, guideline panels, and policymakers should consult the full published article (JAMA) or the PMC full text for the complete dataset and authors' conclusions before drawing clinical inferences.
This PubMed record is the authoritative bibliographic entry for the JAMA randomized clinical trial of adjuvant nivolumab versus observation after resection for NSCLC (PMID 42224490; PMCID PMC13227333). The PubMed excerpt contains author and affiliation listings and links to the full text but does not include trial methods, results, or conclusions in the displayed content. For full methodological and outcome details, refer to the linked full text in JAMA or the PubMed Central copy.